N@N

iCAD announces availability of its SecondLook Digital with Planmed Nuance Full Field Digital Mammography Systems outside of U.S

^{Published on 2008-12-30 11:07:58, Last Modified on 2008-12-30 11:09:05 - Market Wire}
 

NASHUA, N.H.--([ BUSINESS WIRE ])--iCAD^®, Inc. (Nasdaq: ICAD), an industry-leading provider of Computer-Aided Detection (CAD) solutions, today announced that its SecondLook^® Digital CAD technology customized for use with the Planmed Nuance FFDM system is now available outside of the U.S.

"When analyzing iCAD´s SecondLook Digital CAD with Planmed Nuance Full Field Digital Mammography unit using selenium flat panel detector, it was found that the true positive findings detected at double reading of screening mammograms, were also marked accurately by CAD," said Dr. Martti Pamilo from Terveystalo, the leading private healthcare provider in Finland. "We are excited to see the results of the iCAD´s SecondLook Digital CAD integration to the Nuance FFDM system," said Vesa Mattila, Vice President of Planmed. "As CAD is becoming widely accepted in Europe, iCAD's technology is an important addition to Planmed's digital mammography systems and solutions."

iCAD has received CE mark approval to market and sell its customized solution with Planmed Nuance mammography systems and units have been placed at Terveystalo Breast Cancer Screening Center in Helsinki, Finland.

"Our partnership with Planmed marks an important step in iCAD's mammography strategy," said Ken Ferry, President and CEO of iCAD. "Coupling our SecondLook CAD technology with Planmed's Nuance FFDM system is a key element in our overall goal to increase the use of iCAD's systems in markets around the globe to better enable clinicians to identify breast cancer earlier."

About iCAD, Inc.

iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography (DR) and computed radiography (CR), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT). Currently available in more than 2,200 healthcare centers worldwide, iCAD's solutions aid in the early detection of the most prevalent cancers including breast, colon, prostate and in the future, lung cancer. For more information, call (877) iCADnow or visit [ www.icadmed.com ].

About Planmed Oy and the Planmeca Group

Planmed Oy develops, manufactures, and markets advanced imaging equipment and accessories allowing early detection of breast cancer. The product range covers digital and analogue mammography units, mobile mammography units, stereotactic biopsy devices, and breast positioning systems.

Planmed Oy exports more than 98% of its mammography equipment to over 70 countries worldwide. The principal markets are Europe, Japan, Oceania as well as North and Latin America where the company has considerable market shares. Planmed Oy is part of the Finland-based Planmeca Group that manufactures and markets advanced products for the medical and the dental field. The Group currently employs approximately 2,200 people worldwide and expects a turnover of 550 million euros in 2008.

For more information visit [ www.planmed.com ] or [ www.planmeca.com ].

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:

Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "anticipate", "likely", and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.